Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

EMA' Advisory Committee Recommends Approval For Roche's Two Cancer Drugs

  • The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended conditional approval for Roche Holdings AG's (OTC:RHHBY) mosunetuzumab for relapsed or refractory (R/R) follicular lymphoma (FL).
  • The opinion covers mosunetuzumab for adult patients who have received at least two prior systemic therapies. 
  • The CHMP recommendation is based on the phase 1/2 GO29781 study results.
  • The complete response CR rate was 60%, the objective response rate was 80%, and the median progression-free survival was 17.9 months. 
  • The median duration of response among those who responded was 22.8 months.
  • The CHMP has also backed the approval of Tecentriq (atezolizumab) as an adjuvant treatment, following complete resection and platinum-based chemotherapy, for adults with non-small cell lung cancer (NSCLC).
  • The positive opinion comes for patients with a high risk of recurrence whose tumors express PD-L1≥50% and who do not have EGFR mutant or ALK-positive NSCLC. 
  • The recommendation from the CHMP is based on results from the DFS interim analysis of Phase 3 IMpower010 study. Tecentriq reduced the risk of disease recurrence or death by 57%, compared with best supportive care.
  • Price Action: RHHBY shares are up 0.80% at $47.85 during the market session on the last check Friday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.